A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
January 1, 2016
Cited by 387Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis